Clairity
Boston, Massachusetts, United States · Healthcare, Health Care
Clairity is an AI-powered precision health company transforming medical imaging into a predictive tool for early risk assessment. Its flagship product, Clairity Breast, is the first FDA-cleared platform to estimate a woman’s five-year breast cancer risk directly from a routine mammogram. By shifting care from detection to prevention, Clairity empowers health systems, radiologists, and women to act
Key facts
- Headquarters
- Boston, Massachusetts, United States
- Employees
- 16
- Industries
- Healthcare, Health Care
- Status
- Private
- Website
- clairity.com
- Company page
Recent activity at Clairity
Clairity funding history
| Date | Round | Amount |
|---|---|---|
| Nov 2025 | Series B | $43.0M |
| Oct 2022 | Venture | $6.7M |
| Aug 2022 | Funding Round | $9.6M |
| Feb 2021 | Venture | $3.8M |
Leadership
- Kevin Lalande, Executive Officer, Director
- Joe Cunningham, Director
- Brandon Weaver, Executive Officer
- Phillippe Raffy, Executive Officer
- Gabriella Antici, Director
- Caroline Ivers Reeuwijk, Executive Officer
- Shriram Narayanan, Principal Engineer
- Fresh Guthridge, Chief of Staff
- Jenna Barton, Vice President of Finance
- Kelly Dupasquier, Director Of Product Management
Verified email and direct lines for Clairity’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Clairity in the news
- Clarity.com Founder & CEO Reports Company Paid $3.5 Million for the Domain - Domain Name Journal (Oct 16, 2026)
- Everlywell Brings Clairity’s FDA-Authorized AI Breast Cancer Risk Assessment to Women Nationwide - Business Wire (Oct 01, 2026)
- Introducing RAMPART and Clarity: Open source tools to bring safety into Agent development workflow - Microsoft (May 20, 2026)
- Clairity Breast Is Added to NCCN Guidelines for Breast Cancer Screening and Diagnosis - OncLive (Apr 14, 2026)
- Clairity Becomes the First FDA-Authorized AI Platform for Breast Cancer Prediction – Historic Milestone for Women’s Health - BioSpace (Jun 02, 2025)
- Women Can Now Assess Their Breast Cancer Risk With the Help of A.I. - The New York Times (Oct 01, 2026)
- First Patient Receives FDA-Authorized Clairity Breast - GlobeNewswire (Feb 23, 2026)
- Clairity BREAST receives FDA authorization for AI-based breast cancer risk prediction - News-Medical (Jun 03, 2025)
Companies similar to Clairity
- Handl Health · Healthcare, Health Care
- Ablative Solutions · Healthcare, Health Care
- Ospitek · Healthcare, Health Care
- ZealCare, Inc. · Healthcare, Health Care
- Galectin · Healthcare, Health Care
About Clairity: questions and answers
What does Clairity do?
Clairity is an AI-powered precision health company transforming medical imaging into a predictive tool for early risk assessment. Its flagship product, Clairity Breast, is the first FDA-cleared platform to estimate a woman’s five-year breast cancer risk directly from a routine mammogram. By shifting care from detection to prevention, Clairity empowers health systems, radiologists, and women to act
Where is Clairity headquartered?
Clairity is headquartered in Boston, Massachusetts, United States.
How many employees does Clairity have?
Clairity has about 16 employees.
Has Clairity raised funding?
Yes. Fundz has recorded 4 funding events for Clairity. The most recent, Series B of $43.0M, was in Nov 2025.
Who leads Clairity?
Jenna Barton is a Vice President of Finance at Clairity.
What is the latest news on Clairity?
On Nov 13, 2025, Clairity Raises $43 Million in Series B to Launch AI Platform for Breast Cancer Risk Prediction.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy